Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

906291

	registered interest
	date	17/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Members: Correspondence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter from the hon. Member for Glasgow North West dated 25 April 2018 on myalgic encephalomyelitis.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	145353
	answer	answer is ministerial correction date of answer 22/05/2018 answer text <p>The Parliamentary Under Secretary of State (Lord O’Shaughnessy) responded to the hon. Member on 21 May.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/05/2018 14:14:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4443 label Biography information for Carol Monaghan

907168

	registered interest
	date	18/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Members: Correspondence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter from the hon. Member for Glasgow North West dated 27 April 2018 on Serco Group PLC’s contract with Public Health England.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	145588
	answer	answer is ministerial correction date of answer 23/05/2018 answer text <p>I have responded to the hon. Member’s letter today.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/05/2018 15:05:13 answering member 4067 label Biography information for Steve Brine
	tabling member	4443 label Biography information for Carol Monaghan

595733

	registered interest
	date	07/10/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Health Education
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to raise public awareness of (a) pancreatic cancer and (b) other cancers for which symptoms can be non-specific and have similarities to other benign conditions.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	47460
	answer	answer is ministerial correction date of answer 17/10/2016 answer text <p>Public Health England’s (PHE) Be Clear on Cancer campaigns are designed to raise the public’s awareness of specific cancer symptoms, encourage people with those symptoms to go to the doctor and diagnose cancer at an earlier stage. An early visit to a general practice can make a cancer more treatable, and thereby improve cancer survival rates. These campaigns are delivered by PHE in partnership with the Department and NHS England. There are a number of cancers, including those where symptoms can be non-specific, which are not covered by ‘Be Clear on Cancer’ explicitly.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 17/10/2016 15:58:38 answering member 4080 label Biography information for David Mowat
	tabling member	4443 label Biography information for Carol Monaghan

595738

	registered interest
	date	07/10/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Mortality Rates
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to reduce mortality rates for people diagnosed with pancreatic cancer.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	47270
	answer	answer is ministerial correction date of answer 17/10/2016 answer text <p>NHS services for pancreatic cancer have been significantly improved in recent years. This includes clearer diagnostic pathways; decision making by specialist multi-disciplinary teams; and the centralisation of pancreas surgery within specialist teams.</p><p>However, we know more needs to be done. The Independent Cancer Taskforce’s report,<em> Achieving World-Class Outcomes a Cancer Strategy for England 2015 – 2020</em>, notes that whilst survival to date has improved significantly for some cancers, for other cancers, including pancreatic cancer, it has remained stubbornly low.</p><p>An implementation plan, <em>Achieving World-Class Cancer Outcomes: Taking the strategy forward</em>, was published on 12 May 2016 and we hope to see great progress as it is delivered.</p><p>We know earlier diagnosis of cancer makes it more likely that patients will receive effective treatments so we have committed funding of up to £300 million a year by 2020 to implement recommendation 24 of the report that by 2020, everyone referred with a suspicion of cancer will receive either a definitive diagnosis or the all-clear within 28 days.</p><p>In addition, NHS England has published a service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p>The full service specification can be found at:</p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a02-cncr-panc.pdf" target="_blank">http://www.england.nhs.uk/wp-content/uploads/2013/06/a02-cncr-panc.pdf</a></p><p>The National Institute for Health and Care Excellence (NICE) published updated guideline, <em>Suspected cancer: recognition and referral</em>, in June 2015, to ensure that it reflects latest evidence and can continue to support general practitioners (GPs) to identify patients, including children and young people and urgently refer them as appropriate. NICE noted that 5,000 more lives could be saved each year in England if GPs followed the new guideline, which encourage GPs to think of cancer sooner and lower the referral threshold.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 17/10/2016 16:17:50 answering member 4080 label Biography information for David Mowat
	tabling member	4443 label Biography information for Carol Monaghan

595737

	registered interest
	date	07/10/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding his Department has provided for research on pancreatic cancer in each of the last three years.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	47269
	answer	answer is ministerial correction date of answer 13/10/2016 answer text <p>The information requested is not available. Spend on research funded directly by the Department’s National Institute for Health Research (NIHR) is categorised by Health Research Classification System (HRCS) health categories including ‘cancer’. There are no HRCS health sub-categories, such as for pancreatic cancer or other cancer sites.</p><p> </p><p>Investment in cancer research by the NIHR has risen from £101 million in 2010/11 to £135 million in 2014/15 (the latest available figure). The NIHR works closely with patients, charities and our world-leading life sciences industry to support further research into pancreatic cancer.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 13/10/2016 10:05:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4443 label Biography information for Carol Monaghan

173272

	registered interest
	date	07/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Accident and Emergency Departments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of social care budget changes on A&E attendances.
	tabling member constituency	Glasgow North West
	tabling member printed	John Robertson
	uin	906970
	answer	answer is ministerial correction date of answer 13/01/2015 answer text <p>There has been no assessment made of the effect of social care budget changes on accident and emergency (A&amp;E) attendances. However, the Government has legislated to establish the Better Care Fund from 2015-16 to provide better integrated care. One of the conditions of the Better Care Fund is to improve the delivery of health and social care by preventing people reaching crisis point, and to reduce the quantity of non-elective admissions to acute care, which may serve to ease the pressures on A&amp;E departments.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 13/01/2015 15:13:07 answering member 1439 label Biography information for Norman Lamb
	tabling member	605 label Biography information for John Robertson

428555

	registered interest
	date	10/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: Licensing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans he has to improve the availability of off-patent drugs for novel uses through non-legislative measures.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	902130
	answer	answer is ministerial correction date of answer 17/11/2015 answer text <p>Clinicians can already prescribe off-patent drugs off-label on clinical grounds if they judge this is the right thing to do to meet the individual clinical needs of their patients.</p><br /><p>The Government is keen to accelerate the adoption of innovative medicines and increase the innovative use of existing medicines where the evidence reports clinical benefits and cost effectiveness to patients. To that end, we are seeking a number of initiatives to provide innovation but whilst supporting the aims of the Private Member’s Bill on this subject, we do not believe the proposed mechanism is either practicable and desirable.</p><br /><p>We are working with NHS England, the National Institute for Health and Care Excellence, the General Medical Council and the Medicines and Health products Regulatory Agency to ensure that there is better information available to support clinicians who wish to prescribe off-patent drugs for off-label indications, and to ensure that new evidence is picked up more quickly and reliably and translated into clinical practice and can be fed through into licensing applications.</p><br /><p>A huge amount of work is also going on in the Accelerated Access Review which will support the “pull” of innovation through to clinical practice.</p><br /><p>As part of the debate on the Access to Medical Treatments Bill, we are working with officials in the Department, the Medicines and Healthcare products Regulatory Agency, and the Health and Social Care Information Centre to see how the power in the Bill, if it were to pass, could address the lack of provision of information on new uses for existing medicines via the power to create a database of innovations in order to support evidence-based prescribing.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 902127 question first answered 17/11/2015 17:20:22 answering member 4020 label Biography information for George Freeman
	tabling member	4443 label Biography information for Carol Monaghan

431696

	registered interest
	date	23/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has conducted on the disincentives to prescribing off-patent repurposed drugs.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	17150
	answer	answer is ministerial correction date of answer 01/12/2015 answer text <p>The Department has conducted no such research. Current arrangements already allow off-patent drugs to be prescribed for new purposes where this is the most appropriate clinical treatment course for a patient. Prescribing decisions are a matter for the clinical judgement of the prescriber concerned.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/12/2015 16:49:32 answering member 4020 label Biography information for George Freeman
	tabling member	4443 label Biography information for Carol Monaghan

431700

	registered interest
	date	23/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Off-patent Drugs Bill
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the contribution of 6 November 2015 by the Minister for Community and Social Care, Official Report, column 1307, what the evidential basis is for his statement that the provisions of the Off-patent Drugs Bill would be potentially harmful.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	17208
	answer	answer is ministerial correction date of answer 01/12/2015 answer text <p>The current legal framework allows a clinician to prescribe drugs outside their licensed indication where that will best meet the clinical needs of their patient. This clinical freedom is crucial in delivering appropriate healthcare to groups of patients for whom medicines have not historically been licensed, e.g. children. It is also helpful in enabling prescribers to quickly pick up and apply new evidence that will help patients with particular clinical needs. The Off-Patent Drugs Bill would introduce a legal duty to apply for a licence for off-patent drugs where evidence of effectiveness for a new indication becomes available. This will create an expectation that only licensed uses of drugs are acceptable and therefore that off-label use is not appropriate. This would cause unnecessary delays in patients getting the medicines they need by slowing the rapid uptake of new evidence in clinical practice. This is why we believe the proposed legislation could potentially be harmful.</p><br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/12/2015 16:45:34 answering member 4020 label Biography information for George Freeman
	tabling member	4443 label Biography information for Carol Monaghan

906348

	registered interest
	date	17/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Fatigue Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much funding from the public purse was allocated to biomedical research into Myalgic Encephalomyelitis 2014-2015.
	tabling member constituency	Glasgow North West
	tabling member printed	Carol Monaghan
	uin	145354
	answer	answer is ministerial correction date of answer 22/05/2018 answer text <p>In the period in question, the major National Institute for Health Research (NIHR) funding for biomedical research was through its Biomedical Research Centres and Units. These support research funded by the NIHR itself and also research funded by other public, charity and industry research funders. The level of funding for biomedical research into chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) for each financial year can be found in the table below. The funding for this research came from a combination of funders.</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>£</p></td></tr><tr><td><p>2014-15</p></td><td><p>280,442</p></td></tr><tr><td><p>2015-16</p></td><td><p>295,626</p></td></tr><tr><td><p>2016-17</p></td><td><p>130,958</p></td></tr></tbody></table><p> </p><p>The NIHR Clinical Research Network (CRN) provides the infrastructure that allows high-quality clinical research funded by charities, research funders and life-sciences industry to be undertaken throughout the National Health Service. The level of funding for biomedical research into CFS/ME for each financial year can be found in the table below. The funding for this research came from a combination of the NIHR, the Medical Research Council (MRC) and medical research charities. Expenditure from the CRN coordinating centre itself is also outlined below:</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>CRN funding for research, £</p></td><td><p>Coordinating expenditure, £</p></td></tr><tr><td><p>2014-15</p></td><td><p>134,769</p></td><td><p>17,485</p></td></tr><tr><td><p>2015-16</p></td><td><p>125,176</p></td><td><p>17,796</p></td></tr><tr><td><p>2016-17</p></td><td><p>82,866</p></td><td><p>7,821</p></td></tr></tbody></table><p> </p><p>The MRC spend on research directly relating to CFS/ME can be found in the following table. Research into CFS/ME is a continuing priority for the MRC.</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>£</p></td></tr><tr><td><p>2014-15</p></td><td><p>652,044</p></td></tr><tr><td><p>2015-16</p></td><td><p>287,234</p></td></tr><tr><td><p>2016-17</p></td><td><p>286,197</p></td></tr></tbody></table><p> </p><p>The NIHR and the MRC welcomes funding applications for research into any aspect of human health, including biomedical research into CFS/ME. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. On this basis, it is not possible to say how much funding is planned in the current financial year.</p><p> </p><p>The NIHR recognises that CFS/ME is a debilitating condition and is speaking with the United Kingdom CFS/ME Research Collaborative and patient representatives about how best we can support a joined up approach to high quality research into this complex disorder.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 145355 145356 145357 question first answered 22/05/2018 12:30:42 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4443 label Biography information for Carol Monaghan